Search company, investor...

Stage

Acquired | Acquired

Total Raised

$364.16M

About Symphogen

Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market. The company has advanced the frontier of antibody discovery by creating well-characterized antibody mixtures that address multiple oncology targets in a single drug product. The company has matured its pipeline, currently has two product candidates in the clinic, and is researching promising novel immuno-oncology opportunities. On April 3, 2020, Symphogen was acquired by Servier. Terms of the transaction were not disclosed.

Headquarters Location

Pederstrupvej 93

Ballerup, DK-2750,

Denmark

+45 4526 5050

Loading...

Loading...

Symphogen Patents

Symphogen has filed 33 patents.

The 3 most popular patent topics include:

  • clusters of differentiation
  • immune system
  • immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/7/2022

12/5/2023

Clusters of differentiation, Immune system, Immunology, Transcription factors, Monoclonal antibodies

Grant

Application Date

6/7/2022

Grant Date

12/5/2023

Title

Related Topics

Clusters of differentiation, Immune system, Immunology, Transcription factors, Monoclonal antibodies

Status

Grant

Latest Symphogen News

CTTQ Acquires Global Rights to Clinical Stage Symphogen Immunotherapy

May 23, 2022

publication date: May 23, 2022 Chia Tai‑Tianqing Pharma (CTTQ), a Nanjing subsidiary of Sino Biopharma, will acquire global rights to an anti-LAG3 mAb from Symphogen A/S of Denmark. Sym022 is a mAb that binds LAG3 to block the interaction with MHCII, which increases T cell proliferation and production of cytokines. In two Phase I trials, Sym022 proved itself to be safe and well-tolerated as a monotherapy and in combination with checkpoint inhibitors. Financial details of the transaction were not disclosed. Symphogen is the Antibody Center of Excellence for Servier, a privately held French biopharma. More details.... Share this with colleagues:

Symphogen Frequently Asked Questions (FAQ)

  • Where is Symphogen's headquarters?

    Symphogen's headquarters is located at Pederstrupvej 93, Ballerup.

  • What is Symphogen's latest funding round?

    Symphogen's latest funding round is Acquired.

  • How much did Symphogen raise?

    Symphogen raised a total of $364.16M.

  • Who are the investors of Symphogen?

    Investors of Symphogen include Servier, Genentech, Novo Holdings, PKA, Danica Pension and 10 more.

  • Who are Symphogen's competitors?

    Competitors of Symphogen include Humanetics, ImmunoReagents, Altor BioScience, Merus, Theraclone Sciences and 7 more.

Loading...

Compare Symphogen to Competitors

ImmunoReagents Logo
ImmunoReagents

ImmunoReagents is a manufacturer of antibodies and reagents for the pharmaceutical, biotechnology, life science research, and in vitro diagnostics industries. The company offers a range of products including primary and secondary antibodies, ELISA and Western Blot reagents, and antibody purification tools. ImmunoReagents also provides bulk immunoassay reagents and OEM services for the production of research reagents and diagnostic immunoassays. It was founded in 2005 and is based in Raleigh, North Carolina.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and well-being in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

E
Embera NeuroTherapeutics

Embera NeuroTherapeutics is a clinical-stage pharmaceutical company focused on developing novel treatments for addiction. Their main product, EMB-001, is designed to reduce cravings and loss of control in individuals by targeting multiple pathways in the stress response system. The company's research primarily addresses the unmet medical needs in the treatment of cocaine use disorder and smoking cessation. It was founded in 2005 and is based in Sudbury, Massachusetts.

N
NovaDigm Therapeutics

NovaDigm Therapeutics is a biotechnology company focused on developing immunotherapeutics and preventative vaccines for fungal and bacterial diseases. Their main product, NDV-3A, is a vaccine candidate designed to reduce the severity of diseases caused by pathogens such as Candida and Staphylococcus aureus, including drug-resistant strains. The company's primary market includes healthcare providers and patients dealing with recurrent or life-threatening fungal and bacterial infections. It is based in Grand Forks, North Dakota.

M
ModiQuest

ModiQuest is a biotechnology company focused on developing novel therapeutics for inflammatory diseases, particularly in the domain of rheumatoid arthritis. The company specializes in using recombinant antibody technology to create therapeutic leads aimed at treating rheumatoid arthritis and other inflammatory conditions. ModiQuest primarily serves the biopharmaceutical industry with its therapeutic leads designed for co-development or outlicensing. It was founded in 2004 and is based in Netherlands.

AdAlta Logo
AdAlta

AdAlta is a biotechnology company focused on the development of i-body drugs for the treatment of fibrotic diseases. The company's main offerings include a drug discovery platform that creates small, antibody-like proteins for therapeutic intervention in diseases, and a pipeline of these i-bodies aimed at treating conditions such as fibrosis and immuno-oncology. AdAlta's technology is also applied in developing cell therapies and imaging solutions for cancer diagnostics. It is based in San Diego, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.